Xencor IncXNCREarnings & Financial Report
Xencor Inc is a clinical-stage biopharmaceutical company focused on developing engineered antibody and protein therapeutics using its proprietary technology platform. Its pipeline targets oncology, autoimmune disorders, and inflammatory diseases, and it collaborates with global pharmaceutical partners to advance candidates addressing unmet medical needs across major markets.
Revenue
$23.9M
Gross Profit
N/A
Operating Profit
$-55.4M
Net Profit
$-67.3M
Gross Margin
N/A
Operating Margin
-231.6%
Net Margin
-281.7%
YoY Growth
-47.5%
EPS
$-1.09
Xencor Inc Q2 FY2024 Financial Summary
Xencor Inc reported revenue of $23.9M (down 47.5% YoY) for Q2 FY2024, with a net profit of $-67.3M (down 206.7% YoY) (-281.7% margin).
Key Financial Metrics
| Total Revenue | $23.9M |
|---|---|
| Net Profit | $-67.3M |
| Gross Margin | N/A |
| Operating Margin | -231.6% |
| Report Period | Q2 FY2024 |
Xencor Inc Annual Revenue by Year
Xencor Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $125.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $125.6M |
| 2024 | $110.5M |
| 2023 | $174.6M |
| 2022 | $164.6M |
Xencor Inc Quarterly Revenue & Net Profit History
Xencor Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $28.2M | -46.5% | $-6.7M | -23.6% |
| Q3 FY2025 | $21.0M | +18.0% | $-6.0M | -28.7% |
| Q2 FY2025 | $43.6M | +82.4% | $-30.8M | -70.7% |
| Q1 FY2025 | $32.7M | +104.6% | $-48.4M | -147.9% |
| Q4 FY2024 | $52.8M | +3.6% | $-45.6M | -86.3% |
| Q3 FY2024 | $17.8M | -69.9% | $-46.3M | -260.1% |
| Q2 FY2024 | $23.9M | -47.5% | $-67.3M | -281.7% |
| Q1 FY2024 | $16.0M | -15.6% | $-73.4M | -459.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.0M | $23.9M | $17.8M | $52.8M | $32.7M | $43.6M | $21.0M | $28.2M |
| YoY Growth | -15.6% | -47.5% | -69.9% | 3.6% | 104.6% | 82.4% | 18.0% | -46.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $896.9M | $840.6M | $999.9M | $951.9M | $904.7M | $879.4M | $868.8M | $875.5M |
| Liabilities | $297.1M | $291.9M | $294.0M | $277.9M | $264.8M | $259.1M | $243.5M | $239.9M |
| Equity | $600.1M | $550.5M | $708.9M | $677.6M | $639.9M | $620.4M | $625.3M | $635.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-56.9M | $-67.3M | $-28.1M | $-49.8M | $-16.2M | $-36.4M | $-30.8M | $-51.7M |